Govt Amends NDCT Rules to Cut Drug Approval Timelines
ECONOMY & POLICY

Govt Amends NDCT Rules to Cut Drug Approval Timelines

The Union Ministry of Health and Family Welfare has recently notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at reducing regulatory burden and improving Ease of Doing Business in the pharmaceutical sector. The changes focus on simplifying approval processes and significantly shortening timelines for drug development and clinical research.
Under the revised framework, the requirement for pharmaceutical companies to obtain a test licence from the Central Drugs Standard Control Organization (CDSCO) for non-commercial manufacture of small quantities of drugs for research or analysis has been replaced with a prior-intimation system. Companies may now proceed after submitting an online intimation, except for a limited category of high-risk drugs such as cytotoxic, narcotic and psychotropic substances. This move is expected to save at least 90 days in the drug development cycle.
For categories where test licences continue to apply, the statutory processing timeline has been reduced from 90 days to 45 days. With CDSCO handling nearly 30,000–35,000 such applications annually, the reform is expected to substantially ease compliance requirements for the industry.
In another major change, prior approval for certain low-risk Bioavailability and Bioequivalence (BA/BE) studies has been waived. These studies can now commence based on a simple online intimation, benefiting the generic pharmaceutical segment. CDSCO processes around 4,000–4,500 BA/BE applications each year.
Dedicated online modules on the National Single Window System and the SUGAM portal will support seamless implementation. Overall, the reforms are expected to accelerate research, optimise regulatory resources, and strengthen India’s position as a global hub for pharmaceutical R&D.  

The Union Ministry of Health and Family Welfare has recently notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, aimed at reducing regulatory burden and improving Ease of Doing Business in the pharmaceutical sector. The changes focus on simplifying approval processes and significantly shortening timelines for drug development and clinical research.Under the revised framework, the requirement for pharmaceutical companies to obtain a test licence from the Central Drugs Standard Control Organization (CDSCO) for non-commercial manufacture of small quantities of drugs for research or analysis has been replaced with a prior-intimation system. Companies may now proceed after submitting an online intimation, except for a limited category of high-risk drugs such as cytotoxic, narcotic and psychotropic substances. This move is expected to save at least 90 days in the drug development cycle.For categories where test licences continue to apply, the statutory processing timeline has been reduced from 90 days to 45 days. With CDSCO handling nearly 30,000–35,000 such applications annually, the reform is expected to substantially ease compliance requirements for the industry.In another major change, prior approval for certain low-risk Bioavailability and Bioequivalence (BA/BE) studies has been waived. These studies can now commence based on a simple online intimation, benefiting the generic pharmaceutical segment. CDSCO processes around 4,000–4,500 BA/BE applications each year.Dedicated online modules on the National Single Window System and the SUGAM portal will support seamless implementation. Overall, the reforms are expected to accelerate research, optimise regulatory resources, and strengthen India’s position as a global hub for pharmaceutical R&D.  

Next Story
Real Estate

BXB Estates Sets AED 110 Million Jumeirah Golf Estates Record

BXB Estates has completed an AED 110 million residential transaction at Jumeirah Golf Estates, setting a new sales record for the prestigious Dubai residential community.Negotiated by Alfie Tabrez, Managing Partner of BXB Estates, the deal surpassed the previous record of AED 58 million for a completed ready villa in the development.The six-bedroom residence offers 21,714 sq ft of built-up space on a 15,873-sq-ft plot. It features nine bathrooms, four living lounges, a home office, bar lounge, private cinema and rooftop terrace.The property also includes a dedicated wellness area comprising a ..

Next Story
Infrastructure Urban

SECR Floats Rs 6,019 Mn EPC Tender For Paradol Nagpur Link

South East Central Railway (SECR) has invited bids for an Engineering, Procurement and Construction (EPC) contract to build a new broad gauge single line between Paradol Takeoff Point and Nagpur Road Station in Chhattisgarh. The contract carries an estimated cost of Rs 6,019.0 mn and requires an earnest money deposit of Rs 120.4 mn. The work is framed as an EPC assignment intended to strengthen regional rail infrastructure. The tender, issued under number CAO-C-BSP-26-27-15, specifies a completion period of 730 days and a bid validity of 180 days. Two pre-bid meetings are scheduled for 24 Augu..

Next Story
Infrastructure Transport

Indian Railways Reports Nine Per Cent Rise In July Freight Loading

Indian Railways handled 141.3 million tonnes (141.3 mn t) of freight in July, marking a rise of nine per cent year on year. Freight loading maintained a positive trajectory across the network compared with the same month last year. Passenger traffic also increased in July, contributing to higher overall network utilisation. The July outcome continued a pattern of steady monthly gains, reflecting gradual improvement in industrial and logistics activity. The growth in freight volumes reflected stronger demand across multiple sectors and improvements in logistics and train turnarounds. Enhanced r..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement